• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Controls on clozapine must be reviewed.
【24h】

Controls on clozapine must be reviewed.

机译：必须审查氯氮平的控制措施。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

After a long delay due to concern about agranulocytosis, in 1993 clozapine was approved for use in Australia, but with unique restrictions: it was only available through hospitals, for the treatment of refractory schizophrenia, and it could only be used in accord with a Protocol to which both doctors and patients had to promise to conform. The Protocol's requirements included: a full blood count each month; results had to be reviewed by the prescribing doctor and pharmacist; and the patient had to be seen at that time (each month) by the doctor. A national system was established to record and monitor blood results. There was an evaluation of the first 3 years of haematological monitoring, in terms of prevention of deaths.
机译：由于担心粒细胞缺乏症，导致长时间的延迟后，1993年，氯氮平被批准在澳大利亚使用，但有独特的限制：氯氮平只能通过医院获得，用于治疗难治性精神分裂症，并且只能按照议定书的规定使用医生和患者都必须承诺要遵守。 《议定书》的要求包括：每月进行全血细胞计数;结果必须由处方医生和药剂师进行审查;并且必须在那个时间（每个月）去看医生。建立了一个国家系统来记录和监测血液结果。就预防死亡而言，对血液学监测的前三年进行了评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号